Clinical Profile of Newly Diagnosed Multiple Myeloma: A SingleCentre Descriptive Study
International Journal of Drug Delivery Technology · 09.04.2026 · 16 (6s)
DOI: 10.25258/ijddt.16.6s.74 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 09.04.2026. Verfasst von Akshay Mehta und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Multiple myeloma (MM) is a plasma cell malignancy characterized by heterogeneous clinical presentation and variable disease burden at diagnosis. Patterns of presentation may differ across healthcare settings, particularly where referral delays and resource constraints influence stage at detection. This study aimed to describe the baseline clinical and molecular characteristics of newly diagnosed MM patients at a tertiary care centre and evaluate their association with Revised International Staging System (R-ISS) stage.
Methods
This prospective observational study included 62 patients with newly diagnosed multiple myeloma evaluated over a one-year period at a tertiary care centre in North India. Diagnosis and staging were performed using the Revised International Myeloma Working Group criteria and the Revised International Staging System (R-ISS). Clinical features, laboratory parameters, imaging findings, bone marrow characteristics, and cytogenetic abnormalities detected by fluorescence in situ hybridization were analyzed. Associations between baseline variables and disease stage were assessed using chi-square and fisher’s tests.
Results
The median age was 62 years (range: 35–75), and 36/62 (58.1%) patients were male. Stage II and stage III disease were observed in 28/62 (45.2%) and 34/62 (54.8%) patients, respectively; no patients presented with stage I disease. Severe anemia (24/62, 38.7%), hypoalbuminemia (35/62, 56.5%), elevated beta-2 microglobulin (49/62, 79%), and elevated LDH (42/62, 67.7%) were significantly associated with stage III disease (p≤0.001). Cytogenetic abnormalities were detected in 33/62 (53.3%), including high-risk abnormalities in 20/62 (32.3%).
Conclusion
In this single-centre cohort, most patients presented with R-ISS stage II–III disease and significant biochemical abnormalities. Hemoglobin, serum albumin, beta-2 microglobulin, and LDH were significantly associated with advanced stage. These routinely available parameters may support initial risk assessment at diagnosis, particularly in settings where access to comprehensive molecular testing is limited.
Zitieren
APA
Mehta, A., Bhagat, M., Singh, A., Dhooria, H. P., & Paul, D. (2026). Clinical Profile of Newly Diagnosed Multiple Myeloma: A SingleCentre Descriptive Study. International Journal of Drug Delivery Technology, 16(6s). https://doi.org/10.25258/ijddt.16.6s.74
Vancouver
Mehta A, Bhagat M, Singh A, Dhooria HP, Paul D. Clinical Profile of Newly Diagnosed Multiple Myeloma: A SingleCentre Descriptive Study. International Journal of Drug Delivery Technology. 2026;16(6s). doi:10.25258/ijddt.16.6s.74
BibTeX
@article{Mehta2026,
author = {Mehta, Akshay and Bhagat, Monica and Singh, Amandeep and Dhooria, Harmeet Pal and Paul, Davinder},
title = {Clinical Profile of Newly Diagnosed Multiple Myeloma: A SingleCentre Descriptive Study},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {6s},
doi = {10.25258/ijddt.16.6s.74}
}
EUVIMED